Vedolizumab for the treatment of ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 2, 2016, Pages 165-175

  Stallmach, Andreas ^a   Schmidt, Carsten ^a   Teich, Niels ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Internistische Gemeinschaftspraxis Für Verdauungs Und Stoffwechselkrankheiten Leipzig Und Schkeuditz   (Germany)

Author keywords

efficacy; pharmacokinetics; side effects; ulcerative colitis; Vedolizumab

Indexed keywords

AZATHIOPRINE; ETROLIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PF 00547659; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; INTEGRIN; INTEGRIN ALPHA4BETA7;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FATIGUE; FEVER; HEADACHE; HUMAN; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; REMISSION; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; INTEGRINS; MOLECULAR TARGETED THERAPY; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84956745792     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1123618     Document Type: Article

References (63)

1. Papers of special note have been highlighted as
2. • of interest
3. •• of considerable interest
4. Cosnes J, Gower-Rousseau C, Seksik P., et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140 (6): 1785-1794
5. Molodecky NA, Soon IS, Rabi DM., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142 (1): 46-54 e42; quiz e30
6. Dignass A, Preiss JC, Aust DE., et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol. 2011; 49 (9): 1276-1341
7. Dignass A, Lindsay JO, Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012; 6 (10): 991-1030
8. Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroentero. 2014; 20 (12): 3146-3152
9. Samaan MA, Bagi P, Vande Casteele N., et al. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am. 2014; 43 (3): 479-494
10. Bressler B, Marshall JK, Bernstein CN., et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015; 148 (5): 1035-1058 e1033
11. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010; 24 (2): 167-182
12. Stallmach A, Dennler U, Marschall U., et al. Patient-relevant endpoints in inflammatory bowel diseases-have changes occurred in Germany over the past twelve years? J Crohns Colitis. 2015; 9 (5): 390-397
13. Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-Adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs. 2014; 74 (3): 297-311
14. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998; 114 (5): 1066-1090
15. Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003; 348 (1): 68-72
16. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013; 29 (4): 397-404
17. Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohns disease and ulcerative colitis. Expert Opin Drug Saf. 2015; 14 (9): 1473-1479
18. Soler D, Chapman T, Yang LL., et al. The binding specificity and selective antagonism of vedolizumab, an anti-Alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009; 330 (3): 864-875
19. Zhi K, Li M, Zhang X., et al. alpha4beta7 Integrin (LPAM-1) is upregulated at atherosclerotic lesions and is involved in atherosclerosis progression. Cellular Physiology Biochemistry: International Journal Experimental Cellular Physiology, Biochemistry, Pharmacology. 2014; 33 (6): 1876-1887
20. Ciccia F, Guggino G, Rizzo A., et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015; 74 (9): 1739-1747
21. Briskin M, Winsor-Hines D, Shyjan A., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997; 151 (1): 97-110
22. Ala A, Brown D, Khan K., et al. Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates. Dig Dis Sci. 2013; 58 (9): 2528-2541
23. Fedyk ER, Wyant T, Yang LL., et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012; 18 (11): 2107-2119
24. Haanstra KG, Hofman SO, Lopes Estevao DM., et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunology. 2013; 190 (5): 1961-1973
25. Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. mABS. 2013; 5 (6): 842-850
26. Wyant T, Leach T, Sankoh S., et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015; 64 (1): 77-83
27. Hesterberg PE, Winsor-Hines D, Briskin MJ., et al. Rapid resolution of chronic colitis in the cotton-Top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996; 111 (5): 1373-1380
28. Feagan BG, McDonald JW, Greenberg G. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology. 2000; 118 (4 Pt 1): A874
29. Parikh A, Leach T, Wyant T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012; 18 (8): 1470-1479
30. Rosario M, Dirks NL, Gastonguay MR., et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohns disease. Aliment Pharmacol Ther. 2015; 42 (2): 188-202
31. Feagan BG, Rutgeerts P, Sands BE., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369 (8): 699-710
32. Sandborn WJ, Feagan BG, Rutgeerts P., et al. Vedolizumab as induction and maintenance therapy for Crohns disease. N Engl J Med. 2013; 369 (8): 711-721
33. Sands BE, Feagan BG, Rutgeerts P., et al. Effects of vedolizumab induction therapy for patients with Crohns disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147 (3): 618-627 e613
34. Milch C, Wyant T, Xu J., et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013; 264 (1-2): 123-126
35. Stüve O, Marra CM, Jerome KR., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006; 59 (5): 743-747
36. Sandborn WJ, Feagan BG, Marano C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology. 2014; 146 (1): 85-95; quiz e14-85
37. Feagan BG, Greenberg GR, Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005; 352 (24): 2499-2507
38. Parikh A, Fox I, Leach T., et al. Long-Term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19 (8): 1691-1699
39. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Risk-management-plan-summary/human/002782/WC500163289.pdf
40. http://www.ema.europa.eu/docs/en-GB/document-library/PIP-decision/WC500180832.pdf
41. Baumgart DC, Atreya R, Bachmann O., et al. Vedolizumab for inflammatory bowel disease in clinical practice-experience for a prospective German registry. ueg Journal. 2015; 3 (Suppl. 1): A18, OP053
42. Amiot A, Peyrin-Biroulet L, Stefanescu C., et al. The French real-life experience of vedolizumab: efficacy and safety in ulcerative colitis: a prospective oberservational multicenter cohort study. ueg Journal. 2105; 3 (Suppl. 1): A18, OP054
43. Shelton E, Allegretti JR, Stevens B., et al. Efficacy of vedolizumab as induction therapy in refractory IBD Patients: A multicenter cohort. Inflamm Bowel Dis. 2015 Dec; 21 (12): 2879-2885
44. Jin Y, Lin Y, Lin LJ., et al. Meta-Analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World Journal of Gastroenterology: WJG. 2015; 21 (20): 6352-6360
45. Bickston SJ, Behm BW, Tsoulis DJ., et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane DB SYST REV. 2014; 8: CD007571
46. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterology Journal. 2014; 2 (5): 333-344
47. Dulai PS, Mosli M, Khanna R., et al. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015; 35 (4): 412-423
48. Colombel JF, Sands BE, Hanauer SB., et al. Long-Term safety of vedolizumab for the treatment of ulcerative colitis or Crohns disease. Am J Gastroenterol. 2013; 108 (Suppl1): S502
49. Rutgeerts P, Sandborn WJ, Feagan BG., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-2476
50. Sandborn WJ, van Assche G, Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology. 2012; 142 (2): 257-265 e251-253
51. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD-The role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013; 38 (10): 1188-1197
52. Fausel R, Afzali A. Biologics in the management of ulcerative colitis-comparative safety and efficacy of TNF-Alpha antagonists. Ther Clin Risk Manag. 2015; 11: 63-73
53. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014; 13 (1): 24-30
54. Takeda G. Dossier zur Nutzenbewertung gemäß § 35a SGB V; Vedolizumab (Entyvio®); Modul 4 A. Colitis ulcerosa [Internet]. 2014 [cited 2015 Sep 5]. Available from: https://www.g-ba.de/informationen/nutzenbewertung/125/
55. Gisbert JP, Marin AC, McNicholl AG., et al. Systematic review with meta-Analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015; 41 (7): 613-623
56. Schreiber S, Dignass AU, Hartmann H., et al. Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung. Zeitschrift Für Gastroenterologie. 2015; 53 (6): 591-602
57. Gisbert JP, Chaparro M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? Scand J Gastroenterol. 2015; 50 (4): 379-386
58. Laharie D, Bourreille A, Branche J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380 (9857): 1909-1915
59. Bürger M, Schmidt C, Teich N., et al. Medical therapy of active ulcerative colitis. Viszerlamedizin. Gastrointest Med Surg. 2015; 15 (4): 236-245
60. Solberg IC, Lygren I, Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44 (4): 431-440
61. van Deen WK, van Oijen MG, Myers KD., et al. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014; 20 (10): 1747-1753
62. Lee HS, Park SH, Yang SK., et al. Long-Term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. Journal of Crohns & Colitis. 2015; 9 (2): 147-155
63. Tew GW, Hackney JA, Gibbons D., et al. Association between response to etrolizumab and expression of integrin alpha E and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology. 2015 Oct 29. pii: S0016-5085(15)01574-7. doi: 10.1053/j.gastro.2015.10.041. [Epub ahead of print]